Advertisement

Mycopathologia

, Volume 174, Issue 3, pp 215–221 | Cite as

Effects of Antifungal Agents Alone and in Combination Against Candida glabrata Strains Susceptible or Resistant to Fluconazole

  • Izabel Almeida Alves
  • Laíssa Arévalo Bandeira
  • Débora Alves Nunes MarioEmail author
  • Laura Bedin Denardi
  • Louise Vignoles Neves
  • Janio Morais Santurio
  • Sydney Hartz Alves
Article

Abstract

The rise of Candida spp. resistant to classic triazole antifungal agents has led to a search for new therapeutic options. Here, we evaluated combinations of antifungals in a checkerboard assay against two groups of Candida glabrata strains: one containing fluconazole-susceptible clinical isolates (FS) and another containing fluconazole-resistant laboratory derivative (FR). The most synergistic combination observed was amphotericin B + flucytosine (synergistic for 61.77 % of FS strains and 76.47 % of FR strains). The most antagonistic combination observed was ketoconazole + flucytosine (FS 61.77 % and FR 55.88 %). Surprisingly, most combinations evidenced indifferent interactions, and the best synergism appeared when amphotericin B and flucytosine were combined against both groups of isolates.

Keywords

Candida glabrata Resistance Antifungal drug combination 

References

  1. 1.
    Arai R, Sugita T, Nishikawa A. Reassessment of the in vitro synergistic effect of fluconazole with the non-steroidal anti-inflammatory agent ibuprofen against Candida albicans. Mycoses. 2005;2005(48):38–41.CrossRefGoogle Scholar
  2. 2.
    Baltch AL, Bopp LH, Smith RP, Ritz WJ, Michelsen PB. AntiCandidal effects of voriconazole and caspofungin, singly and in combination, against Candida glabrata, extracellularly and intracellularly in granulocyte-macrophage colony stimulating factor (GM-CSF)-activated human monocytes. J Antimicrob Chemother. 2008;62:1285–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Barchiesi F, Gallo D, Caselli F, Di Francesco LF, Arzeni D, Giacometti A, Scalise G. In vitro interactions of itraconazole with flucytosine against clinical isolates of Cryptococcus neoformans. J Antimicrob Chemother. 1999;44:65–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Barchiesi F, Spreghini E, Maracci M, Fothergill AW, Badassarri I, Rinaldi MG, Scalise G. In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. Antimicrob Agents Chemother. 2004;48:3317–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Barchiesi F, Spreghini E, Fothergill AW, Arzeni D, Graganti G, Giannini D, Rinaldi MG, Scalise G. Caspofungin in combination with amphotericin B against Candida glabrata. Antimicrob Agents Chemother. 2005;49:2546–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Bennett JE, Izumikawa K, Marr KA. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother. 2004;48:1773–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Block E, Bennett JE. The combined effect of 5-fluorocytosine and amphotericin B in the therapy of murine cryptococcosis. Proc Soc Exp Biol Med. 1973;142:476–80.PubMedGoogle Scholar
  8. 8.
    Cantón E, Pemán J, Gobernado M, Viudes A, Ana Espinel-Ingroff A. Synergistic Activities of Fluconazole and Voriconazole with Terbinafine against Four Candida Species Determined by Checkerboard, Time-Kill, and Etest Methods. Antimicrob Agents Chemother. 2005;49:1593–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Clinical and Laboratory Standards Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing yeasts 3rd ed. Approved standard M27-A3. 2008;Wayne, PA.Google Scholar
  10. 10.
    Colombo AL, Nucci M, Park BJ, Nouer AS, Arthington-Skaggs B, Matta DA, Warnock D, Morgan J. The Brazilian Network Candidemia Study. Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers. J Clin Microbiol. 2006;44:2816–23.PubMedCrossRefGoogle Scholar
  11. 11.
    Dumainn V, Eyrolle L, Baixench MT, Paugam A, Larousserie F, Padoin C, Tod M, Salmon D. Successful treatment of prosthetic knee Candida glabrata infection with caspofungin combined with flucytosine. Int J Antimicrob Chemother. 2008;31:398–9.CrossRefGoogle Scholar
  12. 12.
    Denning DW, Baily GG, Hood SV. Azole resistance in Candida. Eur J Clin Microbiol Infect Dis. 1997;16:261–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Fekete-Forgács K, Gyurc L, Lenkey B. Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans. Mycoses. 1999;43:273–9.CrossRefGoogle Scholar
  14. 14.
    Garcia-Effron G, Mellado E, Gomez-Lopez A, Alcazar-Fuolli L, Cuenca-Estrella M, Rodriguez-Tudela JL. Differences in interactions between azole drugs related to modifications in the 14-sterol demethylase gene (cyp51a) of Aspergillus fumigatus. Antimicrob Agents Chemother. 2005;49:2119–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Ghannoum MA, Isham N. Abstr. 29th Annu. Meet. Eur. Group Blood and Marrow Transplant. 2003; Abstr. 671. Google Scholar
  16. 16.
    Hossain MA, Reyes GH, Long LA, Mukherjee PK, Ghannoum MA. Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J Antimicrob Chemother. 2003;51:1427–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Johnson MD, Macdougall C, Ostrosky L, Perfect JR, Rex JH. Combination antifungal therapy. Antimicrob Agents Chemother. 2004;48:693–715.PubMedCrossRefGoogle Scholar
  18. 18.
    Lewis RE, Diekema DJ, Messes SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J Antimicrob Chemother. 2002;49:345–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Odds FC. Interactions among amphotericin b, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro. Antimicrob Agents Chemother. 1982;22:763–70.PubMedCrossRefGoogle Scholar
  20. 20.
    Oz Y, Akşit F, Kiraz N, Kiremitçi A. In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates. Mikrobiyol Bul. 2008;42:149–55.PubMedGoogle Scholar
  21. 21.
    Pina-Vaz C, Sansonetty F, Rodrigues AG, Martinez-De-Oliveira J, Fonseca AF, Mårdh PA. Antifungal activity of ibuprofen alone and in combination with fluconazole against Candida species. J Med Microbiol. 2000;49:831–40.PubMedGoogle Scholar
  22. 22.
    Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis. 2004;48:201–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–63.PubMedCrossRefGoogle Scholar
  24. 24.
    Polak A. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy. 1987;33:381–95.PubMedCrossRefGoogle Scholar
  25. 25.
    Sanguinetti M, Posteraro B, Fiori B, Ranno S, Torelli S, Fadda G. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49:668–79.PubMedCrossRefGoogle Scholar
  26. 26.
    Scheid LA, Mario DAN, Kubiça TF, Santurio JM, Alves SH. In vitro activities of antifungal agents alone and in combination against fluconazole-susceptible and -resistant strains of Candida dubliniensis. Braz J Infect Dis. 2012;16(78):81.Google Scholar
  27. 27.
    Siau H, Kerridge D. The effect of antifungal drugs in combination on the growth of Candida glabrata in solid and liquid media. J Antimicrob Chemother. 1998;41:357–66.PubMedCrossRefGoogle Scholar
  28. 28.
    Silva EG, Paula CR, Dias AL, Chan MR, Ruiz LD, Gambale V, Prates R, Ribeiro MS. Combination efficacy of voriconazole and amphotericin b in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans. Mycopathologia. 2010;24:31–6.Google Scholar
  29. 29.
    Tobudic S, Kratzer C, Lassnigg A, Graninger W, Prestrl E. In vitro activity of antifungal combinations against Candida albicans biofilms. J Antimicrob Chemother. 2010;65:271–4.PubMedCrossRefGoogle Scholar
  30. 30.
    White DJ, Habib AR, Vanthuyne A, Langford S, Symonds M. Combined topical flucytosine and amphotericin B for refractory vaginal Candida glabrata infections. Sex Transm Inf. 2001;77:212–3.CrossRefGoogle Scholar
  31. 31.
    Vazquez JA. Combination antifungal therapy against Candida species: the new frontier—are we there yet? Med Mycol. 2003;41:355–68.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Izabel Almeida Alves
    • 1
  • Laíssa Arévalo Bandeira
    • 1
  • Débora Alves Nunes Mario
    • 1
    Email author
  • Laura Bedin Denardi
    • 1
  • Louise Vignoles Neves
    • 1
  • Janio Morais Santurio
    • 1
  • Sydney Hartz Alves
    • 1
  1. 1.Departamento de Microbiologia e ParasitologiaUniversidade Federal de Santa MariaSanta MariaBrazil

Personalised recommendations